Global HIV care in general/family practice;La prise en charge en médecine générale du patient atteint par le VIH

Revue Medicale de Bruxelles

Volumn 26, Issue 4, 2005, Pages

  Semaille, P ^a,b   Dubois, S ^a   Gennotte, A F ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b NONE   (Belgium)

Author keywords

Acquired immunodeficiency syndrome; AIDS related opportunistic infections; Antiretroviral agents; General practice; HIV; HIV seroprevalence; Partner counselling and testing; Pregnancy; Prejudice; Preventive measures; Primary care; Side effects

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; AMYLASE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; BCG VACCINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; VIDEX EC; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; AMYLASE BLOOD LEVEL; ANEMIA; ARTICLE; COOPERATION; DIABETES MELLITUS; DIARRHEA; DRUG HYPERSENSITIVITY; DYSPNEA; FATIGUE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENERAL PRACTICE; GENERAL PRACTITIONER; GOUT; HEALTH CARE QUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTRIGLYCERIDEMIA; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE REACTION; INSOMNIA; LACTIC ACIDOSIS; LIFE EXPECTANCY; LIFESTYLE; LIPOATROPHY; LIPODYSTROPHY; MALAISE; MEDICAL CARE; MYALGIA; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PANCREATITIS; PARESTHESIA; PATIENT COUNSELING; PERIPHERAL NEUROPATHY; PREGNANCY; PRIMARY MEDICAL CARE; PSYCHOLOGICAL ASPECT; RASH; REPRODUCTION; RISK REDUCTION; SAFE SEX; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALITY; SIDE EFFECT; SKILL; SKIN ALLERGY; SOCIAL ASPECT; STEVENS JOHNSON SYNDROME; STOMATITIS; THROMBOCYTOPENIA; VIRUS TRANSMISSION; VOMITING;

EID: 26244436626     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. UNAIDS: Report 2004 on the global HIV/Aids epidemic (www.unaids.org)
2. Stratégies concertées du secteur de la prévention du Sida et des IST en Communauté française. Avril 2005. Observatoire du Sida et des sexualités
3. European Centre for the Epidemiological Monitoring of AIDS. HIV/AIDS Surveillance in Europe. November 2004. Report 70. EuroHIV - Institut de Veille Sanitaire
4. Le SIDA en Belgique. Situation au 31 décembre 2004. Rapport semestriel 60. Institut scientifique de la Santé Publique
5. Defraye, Sasse A: Surveillance des MST via un réseau sentinelle de cliniciens en Belgique. Institut Scientifique de Santé Publique, Section Epidémiologie. Bruxelles, 2004
6. Egger M, May M, Chene G et al: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 1178
7. + T Cell Decline in Human Immunodeficiency Virus (HIV). J Infect Dis 2002; 185: 905-14
8. Jeffrey L: T-Cell Subsets in Health, Infectious Disease, and Idiopathic CD4 T Lymphocytopenia. Ann Intern Med 1993; 119: 55-62
9. European Aids clinical society EACS. European treatment guidelines. 2001. (http://www.eacs.ws/guide/index_ns.htm)
10. Rapport du comité d'expert Delfraissy - Prise en charge des personnes infectées par le VIH. Paris, Médecine-Science, Flammarion, 2004
11. Medical Management of HIV infection - 2004 - Johns Hopkins University School of Medicine
12. Yeni PG, Hammer SM, Hirsch MS et al: Treatment for Adult HIV Infection 2004. Recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292: 251-65
13. Phillips AN, Staszewski S, Weber R et al: HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286: 2560-7
14. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. US Dept of Health and Human Services and Henry J. Kaiser Family Foundation. July 2003. http://aidsinfo.nih.gov/guidelines/
15. Aides: fiches thérapeutiques (http://www.aides.org),
16. "Vivre avec le VIH". Plateforme de pre"vention du SIDA fe"vrier 2005, Medscape drug info (http://www.medscape.com).
17. Dariosecq JM et al: Infection VIH: mémento thérapeutique. Paris, Doin, 2003.
18. Hansten PD, Horn JR: The Top 100 Drug Interactions: a guide to Patient Management, 2004
19. Répertoire Commenté des Médicaments: http://www.cbip.be, mars 2005.
20. Wilkinson GR: Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-21
21. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG: Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr 2002; 30: 278-87
22. Friedland GH, Williams A: Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999; 13: S61-72
23. AIDS Institute's - New-York State Department of Health. Promoting Adherence To HIV Antiretroviral Therapy. John Hopkins University School of medicine edition. June 2001 http:// www.hivguidelines.org/public_html/center/ best-practices/ treatment_adherence/pdf/treat_adherence_full.pdf
24. Arrêté royal relatif à l'aide médicale urgente octroyée par les Centres Publics d'Aide Sociale aux étrangers qui séjournent illégalement dans le Royaume (M.B. du 31/12/1996)
25. Dillon et al: Primary HIV Infections Associated with Oral Transmission. Abstract 473. 7th Conference on Retroviruses and Opportunistic Infections - 2000.
26. Lifson AR et al: HIV seroconversion in two homosexual men after receptive oral intercourse with ejaculation: implications for counselling concerning safe sexual practices. J Public Health 80, Issue 12: 1509-11.
27. Schacker T et al: Clinical and epidemiological features of primary HIV Infection. Ann Intern Med 1966; 125: 257-64
28. Quinn TC, Wawer MJ, Sewankambo N et al: Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1. N Engl J Med 2000; 342: 921-9
29. Smith DK, Grohskopf LA, Black RJ et al: Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States. MMWR 2005; 54: 1-20
30. Circulaire Ministérielle relative à l'accueil des enfants infectés par le VIH dans les institutions dépendant de la Communauté française ou subventionnées par elle, 2002
31. Charte d'Ottawa pour la promotion de la santé. Organisation Mondiale de la Santé, 1986